MedTrace Logo

Bioequivalence Study of Idalopirdine Tablets 60 mg

NCT02371707 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-05-07

No results posted yet for this study

Summary

This study aims to establish bioequivalence between two tablet formulations of idalopirdine

Conditions

  • Healthy

Interventions

DRUG

Idalopirdine 60 mg formulation A (test)

Tablet for oral use, single dose

DRUG

Idalopirdine 60 mg formulation B (reference)

Tablet for oral use, single dose

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02371707 on ClinicalTrials.gov